Figure 1.
Pten silencing enhances synovial sarcomagenesis. (A) Schematic of alleles, recombination products, and TATCre injection technique (IRES, internal ribosomal entry site). (B) Kaplan-Meier plots of the nonmorbid fraction of hSS1 (left) or hSS2 (right) mice with Pten genotypes of homozygous wild-type (n = 20 and 16 for hSS1 and hSS2, respectively), heterozygous (n = 9 and 12), or homozygous-floxed (n = 45 and 35), injected at age 1 mo with TATCre in the hindlimb. Pten homozygous floxed mice with wild-type Rosa26, also injected at 1 mo with TATCre, are presented on the hSS1 plot (n = 6). Statistical difference (Log-rank test) between Ptenw/w and Ptenfl/fl for hSS1, P = 0.0004, and for hSS2, P = 0.0173. (C) Photomicrographs of H&E histology examples of monophasic (MSS) and biphasic (BSS) SS18-SSX-induced synovial sarcomas from each Pten genotype in TATCre-injected mice. (D) Photomicrographs after immunohistochemistry on hSS;Ptenfl/fl tumor tissue sections with noted primary antibodies, demonstrating characteristic SS staining patterns. Bars, 25 µm.